Business
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring,
About this update from Fortress Biotech, Inc.
[{"type":"text","content":"NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced a two-day summit hosted by Mayank Mamtani, of B. Riley FBR, Inc., that will feature multiple programs from Fortress’ diversified pipeline. The events will be held virtually on Tuesday, August 18, and Wednesday, August 19, 2020, beginning at 1:00 p.m. ET each day.\n Registration links and webcast information: Please click here to register for the event on Tuesday, August 18, 2020.Please click here to register for the event on Wednesday, August 19, 2020. Following each event, the webcast will be available on the News / Events page, located within the Investors section of Fortress’ website, https://www.fortressbiotech.com/news-media/events, for approximately 30 days. Agenda: Day One: Tuesday, August 18, 2020 Opening Remarks – 1 p.m. ET Lindsay Rosenwald, M.D., Chairman, President & CEO Panel #1 – 1:20 p.m. ET: Journey Medical Corporation Claude Maraoui, President & CEO; Robert Nevin, CCO; Nirav Jhaveri, CFO Panel #2 – 1:50 p.m. ET: Cyprium Therapeutics Lung Yam, M.D., Ph.D., President & CEO; Charles Buchen, M.D., Vice President, Business Development Stephen G. Kaler, M.D., M.P.H., Professor of Pediatrics and Genetics and a physician-scientist in the Center for Gene Therapy, Abigail Wexner Research Institute at Nationwide Children’s Hospital Panel #3 – 2:20 p.m. ET: Avenue Therapeutics (ATXI) Lucy Lu, M.D., President & CEO; Joseph Vazzano, CFO Neil Singla, M.D., Chief Scientific Officer, Lotus Clinical Research, LLC Panel #4 – 2:50 p.m. ET: Mustang Bio (MBIO) – Gene Therapy Manuel Litchman, M.D., President & CEO Harry L. Malech, M.D., Chief, Genetic Immunotherapy Section, National Institute of Allergy and Infectious Diseases, NIH Day Two: Wednesday, August 19, 2020 Oncology Strategy Overview – 1 p.m. ET Lindsay Rosenwald, M.D., Chairman, President & CEO Panel #1 – 1:20 p.m. ET: Mustang Bio (MBIO) – Cancer Cell Therapy Manuel Litchman, M.D., President & CEO Stephen J. Forman, M.D., Professor, Department of Hematology & Hematopoietic Cell Transplantation; Director, T Cell Therapeutics Research Laboratory, City of Hope Panel #2 – 1:50 p.m. ET:...